

Table. Summary of EARS-Net data by pathogen and year (data correct as of 20/03/2012)

Pathogen	Year												
	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011**
Number laboratories by year-end				21	27	40	41	42	44	42	43	40†	41††
<i>E. coli</i>													
Number of isolates				741	991	1256	1445	1656	1785	1926	2064	2170	2210
Ampicillin-R*				62.2%	61.9%	65.0%	67.6%	70.7%	68.3%	70.4%	68.7%	68.4%	71.9%
3GC-R*				3.0%	2.5%	2.6%	4.1%	4.2%	6.7%	7.4%	7.5%	8.3%	9.3%
ESBL-producers*				1.2%	1.3%	1.1%	2.4%	2.5%	4.1%	5.0%	5.8%	6.1%	7.5%
Ciprofloxacin-R*	<i>No data</i>	<i>No data</i>	<i>No data</i>	5.4%	9.5%	12.6%	17.3%	21.5%	22.1%	23.3%	22.3%	23.6%	23.8%
Gentamicin-R*				2.7%	3.9%	5.7%	8.5%	7.7%	9.9%	10.2%	7.7%	9.4%	8.7%
Gentamicin/Amikacin/Tobramycin-R*				2.9%	4.3%	6.1%	8.6%	8.6%	10.6%	11.0%	9.3%	11.8%	12.2%
Carbapenem‡-R*				0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
MDR*				2.4%	3.8%	5.6%	7.7%	9.0%	11.4%	12.1%	10.4%	11.7%	13.0%
Number laboratories by year-end	12	19	20	23	28	41	42	42	44	43	43	40†	41††
<i>S. aureus</i>													
Number of isolates	510	639	815	1042	1140	1323	1424	1412	1393	1303	1309	1251	1096
Number Meticillin-R (or MRSA)	198	249	337	445	480	553	592	592	536	439	355	305	264
Meticillin-R (or MRSA)	38.8%	39.0%	41.3%	42.7%	42.1%	41.8%	41.6%	41.9%	38.5%	33.7%	27.1%	24.4%	24.1%
Number VISA	0	0	0	0	0	0	0	2	1	0	0	0	0
VISA*	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.1%	0.1%	0.0%	0.0%	0.0%	0.0%
Number laboratories by year-end				21	27	40	41	42	44	42	43	40†	41††
<i>E. faecium</i>													
Number of isolates				85	135	187	224	265	330	406	397	392	364
Ampicillin-R*				88.9%	91.0%	95.7%	92.3%	93.9%	93.1%	95.1%	92.9%	95.6%	95.9%
Vancomycin-R	<i>No data</i>	<i>No data</i>	<i>No data</i>	11.1%	19.4%	23.2%	31.7%	37.1%	33.4%	35.7%	38.3%	39.3%	37.4%
HLG-R*				16.7%	53.8%	58.0%	51.4%	44.3%	35.2%	28.1%	39.1%	39.6%	36.8%
MDR*				3.7%	11.4%	18.5%	25.6%	25.6%	22.7%	16.2%	26.7%	24.9%	20.5%
Number laboratories by year-end	12	19	20	23	28	41	42	42	44	42	43	40†	41††
<i>S. pneumoniae</i>													
Number of isolates	157	201	245	278	364	400	401	407	438	447	356	314	327
Penicillin-NS*	19.1%	12.9%	12.2%	11.5%	11.8%	10.3%	11.7%	15.7%	17.4%	23.1%	20.2%	18.2%	19.6%
of which: HLR	0.0%	3.5%	1.6%	1.4%	2.2%	1.8%	3.0%	2.9%	5.7%	6.0%	5.6%	4.8%	6.1%
Int	16.6%	8.0%	10.6%	9.7%	8.8%	7.0%	8.7%	12.5%	11.0%	16.8%	13.8%	12.7%	13.5%
Erythromycin-R*	14.0%	12.0%	12.5%	12.7%	11.6%	14.4%	12.1%	16.1%	16.4%	16.7%	17.3%	15.7%	18.9%
Number laboratories by year-end								36	39	41	42	40†	41††
<i>K. pneumoniae</i>													
Number of isolates								217	244	310	323	326	311
Ampicillin-R*								97.7%	99.2%	99.7%	99.7%	99.1%	100.0%
3GC-R*								10.2%	9.9%	11.4%	11.2%	10.5%	8.0%
ESBL-producers*								8.6%	3.7%	7.7%	8.2%	5.0%	5.6%
Ciprofloxacin-R*	<i>No data</i>	<i>No data</i>	<i>No data</i>	<i>No data</i>	<i>No data</i>	<i>No data</i>	<i>No data</i>	15.3%	18.1%	12.8%	13.0%	10.5%	13.2%
Gentamicin-R*								7.8%	9.9%	10.7%	11.1%	6.8%	7.4%
Gentamicin/Amikacin/Tobramycin-R*								9.2%	11.1%	10.7%	11.1%	7.1%	8.4%
Carbapenem‡-R*								0.0%	0.6%	0.0%	0.0%	0.0%	1.6%
MDR*								11.2%	11.9%	10.6%	11.9%	8.0%	8.4%
Number laboratories by year-end				21	27	40	41	42	44	42	43	40†	41††
<i>E. faecalis</i>													
Number of isolates				168	218	242	290	294	280	301	289	298	265
Ampicillin-R*	<i>No data</i>	<i>No data</i>	<i>No data</i>	8.1%	5.1%	0.8%	3.5%	4.5%	2.2%	0.7%	2.1%	2.0%	0.8%
Vancomycin-R				2.4%	1.4%	1.3%	2.5%	3.7%	2.9%	3.7%	0.7%	0.3%	4.9%
HLG-R*				38.5%	33.9%	41.3%	44.4%	42.4%	36.9%	30.5%	36.7%	29.7%	29.1%
Number laboratories by year-end								36	39	41	42	40†	41††
<i>P. aeruginosa</i>													
Number of isolates								128	177	199	248	222	184
Piperacillin/tazobactam-R*								9.4%	12.6%	9.7%	8.9%	10.0%	2.8%
Ceftazidime-R*								10.6%	11.8%	8.7%	11.8%	9.2%	8.2%
Imipenem/meropenem-R*	<i>No data</i>	<i>No data</i>	<i>No data</i>	<i>No data</i>	<i>No data</i>	<i>No data</i>	<i>No data</i>	11.8%	12.2%	9.3%	10.2%	8.3%	8.2%
Ciprofloxacin-R*								18.0%	22.9%	21.8%	12.1%	13.2%	12.6%
Gentamicin-R*								10.2%	13.3%	9.0%	7.7%	8.7%	6.5%
MDR*								9.5%	12.4%	11.1%	6.4%	6.5%	4.0%

Changes to previous reports are highlighted in **RED****R**, Resistant; **NS**, Non-Susceptible [includes isolates with intermediate (**Int**) and high-level resistance (**HLR**)]**MRSA**, Methicillin-Resistant *S. aureus*; **VISA**, Vancomycin-Intermediate *S. aureus***HLG**, High-Level Gentamicin; **3GC**, 3rd-Generation Cephalosporin (includes cefotaxime, ceftriaxone, ceftazidime and cefpodoxime); **ESBL**, Extended-Spectrum Beta-Lactamase; **MDR**, Multi-Drug Resistant

* Not all isolates tested

** 2011 data provisional to the end of Q4

† In 2010, 3 laboratories stopped processing blood cultures, however coverage of acute hospitals remained at 100%

†† In Q3 2011, one additional laboratory started reporting data

‡ Carbapenems include imipenem, meropenem and ertapenem